Skip to Content
Merck
All Photos(1)

Documents

33156-U

Supelco

TMSI+PYRIDINE, 1:4 (Sylon™ TP)

Synonym(s):

1-(Trimethylsilyl)imidazole - Pyridine mixture, Silylating mixture VII, TMSI+Pyridine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
8077-35-8
MDL number:
MFCD00284770
UNSPSC Code:
12000000
PubChem Substance ID:
329754466
NACRES:
NA.22

packaging

pkg of 1 × 25 mL

concentration

(TMSI+Pyridine, 1:4)

SMILES string

c1ccncc1.C[Si](C)(C)n2ccnc2

InChI

1S/C6H12N2Si.C5H5N/c1-9(2,3)8-5-4-7-6-8;1-2-4-6-5-3-1/h4-6H,1-3H3;1-5H

InChI key

PFVKFOIOKNIZKY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

TMSI+PYRIDINE, 1:4 (Sylon™ TP) may be used as a derivatization reagent for the measurement of liver and plasma precursor sterols using gas chromatography coupled with mass spectrometry while investigating the dual-action glycogenolysis/cholesterolgenesis inhibitors that act through inhibition of both glycogen phosphorylase and CYP51.

Legal Information

Sylon is a trademark of Sigma-Aldrich Co. LLC

related product

Product No.
Description
Pricing

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

3 - Flammable liquids

WGK

WGK 3

Flash Point(F)

62.6 °F - closed cup

Flash Point(C)

17 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
LC25334V
LC22431V
LC21918V
LC19751V
LC16071V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Comparison between Solvent Extraction Using Gas Chromatography Mass Spectrometry Triple Quadrupole (GCMS-QQQ) of Cholesterol and Cholesterol Oxidation Derivatives
A.R. Alina
Middle-East Journal of Scientific Research 13, 13, 43-48 (2013)
H James Harwood et al.
Journal of lipid research, 46(3), 547-563 (2004-12-18)
Diabetic dyslipidemia requires simultaneous treatment with hypoglycemic agents and lipid-modulating drugs. We recently described glycogen phosphorylase inhibitors that reduce glycogenolysis in cells and lower plasma glucose in ob/ob mice (J. Med. Chem., 41: 2934, 1998). In evaluating the series prototype

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service